Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of EPI-589 (DA350101) in Healthy Male Volunteers
jRCT2071210023Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EPI-589 in amyotrophic lateral sclerosis (ALS) (10 cohorts), sponsored by Sumitomo Pharma. Primary endpoints: Pharmacokinetic endpoints and Safety endpoints. Started May 2021; status: completed.
02
Drugs
EPI-589
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2071210023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210023.